QTRX241220C22500
- 0.00
- 0.000.00%
Quanterix Newsroom
Quanterix Faces Nasdaq Compliance Challenge, Aims for Transparency
Express News | Quanterix Announces Receipt of Expected Notice From Nasdaq
Wolf Haldenstein Adler Freeman & Herz LLP Announces That It Is Investigating Quanterix Corporation for Potential Violations of Securities Laws
Express News | Quanterix Corporation Is Now Under Investigation by Johnson Fistel, Llp on Behalf of Shareholders Who Incurred Losses on Their Investments
Quanterix: Strong Growth in Accelerator Services and Strategic Expansion Drive Buy Rating
Express News | Quanterix Corp -Files for Non Timely 10-Q With U.S. SEC
Quanterix Analyst Ratings
Quanterix Shares Are Trading Lower. The Company Reported Q3 Financial Results.
TD Cowen Maintains Quanterix(QTRX.US) With Hold Rating, Maintains Target Price $16
Scotiabank Maintains Quanterix(QTRX.US) With Buy Rating, Maintains Target Price $28
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)
Quanterix (QTRX) Gets a Buy From Scotiabank
TD Cowen Maintains Quanterix(QTRX.US) With Hold Rating, Raises Target Price to $16
Express News | Quanterix Corp : TD Cowen Raises Target Price to $16 From $13.50
Cautious Outlook: Evaluating Quanterix's Mixed Performance Amidst Instrument Sales Weakness and Alzheimer's Testing Prospects
Quanterix Reports Strong Growth and New Innovations
Quanterix Corporation (QTRX) Q3 2024 Earnings Conference Call Transcript Summary
Quanterix Reaffirms 2024 Revenue Guidance Range Of $134M - $138M, Est $136.23M
Quanterix: Goal Is to Complete the Restatement and All Required Filings by the End of 2024 >QTRX
Quanterix: Need to Restate Certain Prior Period Fincl Statements to Correct Non-Cash Errors Related to Those Periods >QTRX